钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者心血管和肾脏不良结局的保护作用
Sodium-Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes.
作者信息
Shahady Edward, Leahy John L
机构信息
Diabetes Master Clinician Program, Fernandina Beach, FL.
University of Vermont College of Medicine, Burlington, VT.
出版信息
Clin Diabetes. 2019 Jul;37(3):211-220. doi: 10.2337/cd18-0064.
Abstract
New treatments for type 2 diabetes are required to demonstrate cardiovascular safety in dedicated cardiovascular outcomes trials (CVOTs). This article reviews available evidence on cardiovascular, renal, and safety outcomes from CVOTs and real-world analyses of sodium-glucose cotransporter 2 inhibitors, along with considerations for their use in clinical practice.
摘要
2型糖尿病的新疗法需要在专门的心血管结局试验（CVOTs）中证明心血管安全性。本文回顾了CVOTs以及钠-葡萄糖协同转运蛋白2抑制剂的真实世界分析中有关心血管、肾脏和安全性结局的现有证据，以及在临床实践中使用这些药物的注意事项。
相似文献
1
Sodium-Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes.
Clin Diabetes. 2019 Jul;37(3):211-220. doi: 10.2337/cd18-0064.
2
Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Adv Ther. 2019 Oct;36(10):2567-2586. doi: 10.1007/s12325-019-01054-w. Epub 2019 Aug 23.
3
Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
Adv Ther. 2019 Oct;36(10):2895-2909. doi: 10.1007/s12325-019-01043-z. Epub 2019 Aug 13.
4
Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials.
Endocr Pract. 2023 Jul;29(7):509-516. doi: 10.1016/j.eprac.2023.04.001. Epub 2023 Apr 8.
5
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Lancet Diabetes Endocrinol. 2016 May;4(5):411-9. doi: 10.1016/S2213-8587(16)00052-8. Epub 2016 Mar 18.
6
Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study.
BMJ Open Diabetes Res Care. 2019 Mar 21;7(1):e000627. doi: 10.1136/bmjdrc-2018-000627. eCollection 2019.
7
The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
Curr Med Res Opin. 2019 Jul;35(7):1283-1295. doi: 10.1080/03007995.2019.1576479. Epub 2019 Feb 15.
8
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials.
Diabetes Ther. 2020 Feb;11(2):369-386. doi: 10.1007/s13300-019-00747-3. Epub 2019 Dec 20.
9
Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY.
Diabetes Obes Metab. 2020 Apr;22 Suppl 1(Suppl 1):46-54. doi: 10.1111/dom.13987.
10
Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.
Eur J Intern Med. 2022 Feb;96:26-33. doi: 10.1016/j.ejim.2021.11.008. Epub 2021 Nov 17.
本文引用的文献
1
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704. doi: 10.1016/S2213-8587(18)30141-4. Epub 2018 Jun 21.
2
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.
Diabetes Metab Syndr Obes. 2018 Apr 12;11:133-148. doi: 10.2147/DMSO.S154602. eCollection 2018.
3
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639. doi: 10.1016/j.jacc.2018.03.009. Epub 2018 Mar 11.
4
Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.
BMJ. 2018 Feb 6;360:k119. doi: 10.1136/bmj.k119.
5
SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?
Diabetes Obes Metab. 2018 Jun;20(6):1531-1534. doi: 10.1111/dom.13255. Epub 2018 Mar 12.
6
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Endocr Pract. 2018 Jan;24(1):91-120. doi: 10.4158/CS-2017-0153. Epub 2018 Jan 17.
7
DECLARE-TIMI 58: Participants' baseline characteristics.
Diabetes Obes Metab. 2018 May;20(5):1102-1110. doi: 10.1111/dom.13217. Epub 2018 Feb 14.
8
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Editors' Expert Forum.
Diabetes Care. 2018 Jan;41(1):14-31. doi: 10.2337/dci17-0057.
9
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
Am J Nephrol. 2017 Dec 13;46(6):462-472. doi: 10.1159/000484633.
10
Introduction: .
Diabetes Care. 2018 Jan;41(Suppl 1):S1-S2. doi: 10.2337/dc18-Sint01.
Zotero 插件